Fetuin-A
Fetuin-A is a liver-produced protein that also comes from fat tissue, blocks insulin signalling and promotes inflammation; levels rise in obesity, fatty liver and type 2 diabetes and fall with weight loss and exercise.
Plain English
Patient-Friendly Explanation
Fetuin-A, also known as alpha-2-Heremans-Schmid glycoprotein, is a protein made mainly by the liver and, to a lesser extent, by fat tissue. It has a day job in mineral handling, helping to keep calcium phosphate from depositing inside blood vessels. It also has a second role that matters for weight and metabolism: it blocks the insulin receptor, the switch on the surface of muscle and fat cells that lets insulin move sugar out of the blood, and it acts as a signal that triggers low-grade inflammation. Mice born without fetuin-A are more sensitive to insulin and resist weight gain when fed a high-fat diet, which is strong evidence that the protein contributes to metabolic dysfunction. In people, blood levels of fetuin-A are raised in obesity, type 2 diabetes and fatty liver disease, and in a long-running study of women a high level predicted the later development of type 2 diabetes. Raised levels track with liver fat and with waist circumference. The picture is not completely simple. Genetic studies that use inherited variation in the fetuin-A gene have not confirmed that the protein directly causes diabetes, and in one carefully characterised group the link with insulin sensitivity disappeared once other metabolic features were taken into account, so fetuin-A is treated as a marker of metabolic dysfunction rather than a proven cause. It is also protective against blood-vessel calcification, so a low level is not automatically favourable in every respect. Encouragingly, the level responds to treatment: it falls after substantial weight loss following bariatric surgery, and three months of moderate exercise lowered it in both blood and fat tissue in a study of adults with obesity.
Medical
Clinical Definition
Fetuin-A (alpha-2-Heremans-Schmid glycoprotein, AHSG) is a 64 kDa glycoprotein secreted predominantly by the liver, with a smaller contribution from adipose tissue, and is classified both as a hepatokine and as an adipokine. It inhibits autophosphorylation of the insulin receptor tyrosine kinase and acts as an endogenous ligand for toll-like receptor 4, thereby promoting insulin resistance and subclinical inflammation, and it stimulates adipocyte triglyceride uptake and hepatic triacylglycerol accumulation. Fetuin-A knockout mice show improved insulin sensitivity and resistance to high-fat-diet weight gain. Circulating concentrations are elevated in obesity, type 2 diabetes and steatotic liver disease, and high baseline fetuin-A independently predicted incident type 2 diabetes in prospective observational studies. In one deeply phenotyped cohort, fetuin-A correlated most strongly with liver fat content (rho 0.28) and more weakly with waist circumference, body mass index and visceral adipose tissue volume, and the association with insulin sensitivity was no longer independent after adjustment for conventional metabolic risk factors. A recent study reported the largest concentrations in obesity without type 2 diabetes and found fetuin-A to be a strong predictor of hepatic steatosis, with approximately 5.6-fold higher odds and an area under the curve of 0.84. A large Mendelian randomisation study did not support a causal effect on diabetes, and fetuin-A is also an inhibitor of vascular calcification, so it carries both harmful and protective associations. Levels decreased after bariatric surgery in morbid obesity and after twelve weeks of moderate exercise in adults with obesity, in both the circulation and subcutaneous adipose tissue. Measurement is currently a research tool rather than part of routine care.
Key Insight
Why It Matters
Fetuin-A gives patients a mechanism for why fatty liver, insulin resistance and weight gain travel together: a liver receiving too much fat secretes a protein that worsens insulin signalling and inflammation. It is not measured in routine practice and it is not a drug target, but it reinforces the clinical message that reducing liver and visceral fat reverses the metabolic signal. Its second role in protecting blood vessels against calcification is a reminder that metabolic markers rarely act in only one direction.
Sources
Reviewed against standard medical references.
Medically reviewed by
Family Physician & Registered Acupuncturist, Accord Medical Clinic. MBBS (NUS), Graduate Diploma in Family Medicine (NUS), Graduate Diploma in Acupuncture (Singapore College of TCM).
Last reviewed: October 2026
This page is general health education, not medical advice. Whether any treatment is appropriate for you is a decision made in consultation after assessment.
